» Articles » PMID: 34337729

The Relevance of Inositols Treatment for PCOS Before and During ART

Overview
Date 2021 Aug 2
PMID 34337729
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Polycystic ovary syndrome (PCOS) is an endo-crine disorder that occurs in 8-10% of women of reproduc-tive age. It is characterized by oligo or anovulation, hyperandrogenism and/or polycystic ovaries, but also by an increased insulin plasma level especially in overweight/obese women or in those with familial diabetes. In the last years, among the insulin sensitizers, the use of the two active isoforms of inositols (myo-inositol and d-chiro-inositol) has been spreading for the treatment of PCOS insulin resistance. Several studies have shown a positive role of inositols both on the metabolic profile of PCOS patients, but also on hormonal parameters. Hence, inositols can positively affect the infertility that characterizes many PCOS patients, acting both on ovarian function and spontaneous ovulation and during IVF procedures, in terms of oocyte quality and pregnancy rate.

Citing Articles

Systematic Review of the roles of Inositol and Vitamin D in improving fertility among patients with Polycystic Ovary Syndrome.

Katyal G, Kaur G, Ashraf H, Bodapati A, Hanif A, Okafor D Clin Exp Reprod Med. 2024; 51(3):181-191.

PMID: 38599886 PMC: 11372307. DOI: 10.5653/cerm.2023.06485.


A Markov-model simulation of IVF programs for PCOS patients indicates that coupling myo-Inositol with rFSH is cost-effective for the Italian Health System.

Beresniak A, Russo M, Forte G, Lagana A, Oliva M, Aragona C Sci Rep. 2023; 13(1):17789.

PMID: 37853019 PMC: 10584971. DOI: 10.1038/s41598-023-44055-0.


Nourishing Kidney Promoting Ovulation Decoction (NKPOD) Attenuates Polycystic Ovary Syndrome by Downregulating miRNA-224.

Guo Y, Tong X, Tang P, Zuo W, Tan Y Evid Based Complement Alternat Med. 2023; 2023:9402155.

PMID: 37123085 PMC: 10139811. DOI: 10.1155/2023/9402155.


Metabolic and Molecular Mechanisms of Diet and Physical Exercise in the Management of Polycystic Ovarian Syndrome.

Scarfo G, Daniele S, Fusi J, Gesi M, Martini C, Franzoni F Biomedicines. 2022; 10(6).

PMID: 35740328 PMC: 9219791. DOI: 10.3390/biomedicines10061305.